A series of clinical cases of severe course of ankylosing spondylitis with ineffectiveness to standard therapy
- Authors: Rumiantceva D.G1, Podryadnova M.V1, Rumyantseva O.A1, Urumova M.M1, Erdes S.F1
-
Affiliations:
- V.A. Nasonova Research Institute of Rheumatology
- Issue: Vol 27, No 13 (2020)
- Pages: 142-146
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/312992
- DOI: https://doi.org/10.18565/pharmateca.2020.13.142-146
- ID: 312992
Cite item
Open Access
Access granted
Abstract
Background. Currently, rheumatology is accumulating more and more data on the factors affecting the effectiveness of genetically engineered biological drugs (GMBDs), and there is no generally accepted algorithm for managing patients with resistance to standard therapy. Description of the clinical case. A description of the clinical cases of three patients with ankylosing spondylitis observed at the V.A. Nasonova Research Institute of Rheumatology in 2011-2019. All patients had a severe course of ankylosing spondylitis with high clinical and laboratory activity, the presence of extra-articular manifestations, and the ineffectiveness of three or more GIBPs. Conclusion. All patients are united by the following signs: male sex, early onset of the disease, high clinical and laboratory activity and the presence of extra-articular manifestations such as uveitis and psoriasis.
Full Text
About the authors
D. G Rumiantceva
V.A. Nasonova Research Institute of Rheumatology
Email: mmiantceva01@gmail.com
M. V Podryadnova
V.A. Nasonova Research Institute of Rheumatology
O. A Rumyantseva
V.A. Nasonova Research Institute of Rheumatology
M. M Urumova
V.A. Nasonova Research Institute of Rheumatology
Sh. F Erdes
V.A. Nasonova Research Institute of Rheumatology
References
- Эрдес Ш.Ф., Бадокин В.В., Бочкова А.Г и др. О терминологии спондилоартритов. Научнопрактическая ревматология. 2015;53(6):657-60. doi: 10.14412/1995-4484-2015-657-660. [Erdes Sh.F, Badokin V.V., Bochkova A.G., et al. About the terminology of spondyloarthritis. Nauchno-prakticheskaya revmatologiya. 2015;53(6):657-60. doi: 10.14412/1995-4484-2015-657-660.
- Van der Heijde D., Ramiro S., Landewe R., et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76(6):978-91. Doi: 10.1136/ annrheumdis-2016-210770.
- Wolbink G.J, et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthr Rheum. 2006;54(3):711-15.doi: 10.1002/art.21671.
- Brambell F.W., Hemmings W.A., Morris I.G. A theoretical model of gamma-globulin catabolism. Nature. 1964;203:1352-54. doi: 10.1038/2031352a0.
- Wolbink G.J., Aarden L.A., Dijkmans B.A. Dealing with immunogenicity of biologicals: assessment and clinical relevance. Curr Opin Rheumatol. 2009;21(3):211-15. Doi: 10.1097/ bor.0b013e328329ed8b.
- de Vries M.K., et al. Immunogenicity does notinfluence treatment with etanercept in patients with ankylosing spondylitis. Ann Rheum Dis. 2009;68(4):531-35. doi: 10.1136/ard.2007.072397.
- Garces S., et al. A preliminary algorithm introducing immunogenicity assessment in the management of patients with RA receiving tumour necrosis factor inhibitor therapies. Ann Rheum Dis. 2014;73(6):1138-43. Doi: 10.1136/ annrheumdis-2013-203296.
- Reid V, Castelino M., Parker B. Harmonised Biologics Pathway for Ankylosing Spondylitis (including non-radiographic axial spondyloarthritis-AS) and Psoriatic Arthritis PsA. 2018. Available at: http://gmmmg. nhs.uk/docs/guidance/GMMMG-AS-PsA-pathway-v4-2a.pdf.
- Ducourau E., Mulleman D., Paintaud G., et al. Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases. Arthr Res Ther. 2011;13(3):R105. Doi: 10.1186/ ar3386.
- Ward M.M., et al. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthr Rheum. 2019;71(10):1599-613.
Supplementary files
